Clinical trials: Metastatic Malignant Neoplasm to Brain
Brain Metastases
ASL in Brain Metastasis MRI Following Gamma Knife Treatment
Arterial spin labeling (ASL) is a non-invasive MRI technique that could help the radiologists to distinguish brain metastasis progression versus radionecrosis following gamma-knife treatment.
- Trial name
- GK-ASL (NCT04833335)
- Testing
- MRI perfusion sequence
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Neoplasm, Brain Neoplasm
Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
The purpose of this study is to determine whether temozolomide can be used as a prophylaxis against brain recurrence in participants with metastatic breast cancer.
- Conditions
- Breast Neoplasm, Brain Neoplasm, Second Neoplasm
- Trial name
- STOP (NCT00638963)
- Testing
- temozolomide
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer (NSCLC)
Lorlatinib in ROS1+ NSCLC With Brain Metastasis
The goal of this Phase II, multicenter, open-label, single-arm clinical trial is to evaluate the intracranial efficacy and safety of lorlatinib in adults with TKI-naïve, advanced ROS1-positive non-small cell lung cancer (NSCLC)…
- Trial name
- NCT07083687
- Testing
- Lorlatinib 100 mg
- Volunteers
- 21 people
- Sponsor
- Hunan Cancer Hospital
Melanoma
[18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis
In this feasibility study, [18F]dabrafenib will be used as radioactive tracer. All patients in this study are diagnosed with advanced melanoma with evidence of brain metastases and are eligible for treatment with dabrafenib, a…
- Trial name
- NCT02700763
- Testing
- [18F]dabrafenib molecular imaging
- Where
- Netherlands
- Volunteers
- 1 people
- Sponsor
- University Medical Center Groningen
Solid Tumors, Brain Metastases
18F ML-10 for Early Detection of Response of Brain Metastases to WBRT
The purpose of this study is to evaluate the potential of [18F]-ML-10 to serve as a non-invasive imaging tool for the early detection of apoptosis in brain metastases in response to radiation therapy.
- Trial name
- NCT00791063
- Testing
- 18F ML-10
- Volunteers
- 10 people
- Sponsor
- Aposense Ltd.
Lung Cancer
Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer
The goal of this clinical research study is to learn how effective the drug pemetrexed (ALIMTA®) is in treating advanced NSCLC in patients with poor performance status (PS) (inability to perform every day activities without…
- Trial name
- NCT00508144
- Testing
- Alimta
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer, Brain Metastases
A Study of the Gene Mutation Status in Cerebrospinal Fluid, Blood and Tumor Tissue of Non-small Cell Lung Cancer Patients With Brain Metastases
Primary lung cancer is one of the most common malignancies in China, with 57 percent of patients being diagnosed at advanced stage. At present, advanced lung cancer has entered the era of precise treatment.
- Conditions
- Lung Cancer, Brain Metastases, Cerebrospinal Fluid, Next-generation Sequencing
- Trial name
- NCT03257735
- Testing
- next-generation sequencing
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Brain Metastases, Adult, Brain Metastases
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
The spread of cancer to the brain is referred to as brain metastases. Brain metastases are a common complication of cancer. This study is being done to determine whether the use of a new imaging agent, 18F-fluciclovine, is able…
- Conditions
- Brain Metastases, Adult, Brain Metastases, Brain Cancer
- Trial name
- NCT04689048
- Testing
- 18F fluciclovine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Baptist Health South Florida
Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
This is a clinical study to compare the efficacy and safety of HBI-8000 combined with nivolumab to Placebo combined with nivolumab in patients with unresectable or metastatic melanoma.
- Trial name
- NCT04674683
- Testing
- HBI-8000 in combination with nivolumab
- Where
- 139 sites in United States, Australia and 15 more
- Volunteers
- 450 people
- Sponsor
- HUYABIO International, LLC.
Brain Metastases, Brain Metastases, Adult
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
This is a pilot imaging study in participants treated with stereotactic radiosurgery (SRS) to treat brain metastasis. The purpose of this study is to see whether 18F-Fluciclovine positron emission tomography (PET) can be used as…
- Conditions
- Brain Metastases, Brain Metastases, Adult, Brain Cancer
- Trial name
- FACILITATE (NCT06048094)
- Testing
- 18F fluciclovine
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Baptist Health South Florida
Breast Cancer, Metastatic Breast Cancer
T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases
TUXEDO-4 is an international, multicentric, single arm, phase II study aiming to gather additional solid evidence of Trastuzumab-Deruxtecan (T-DXd) activity in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-low…
- Trial name
- TUXEDO-4 (NCT06048718)
- Testing
- Trastuzumab-Deruxtecan (T-DXd)
- Where
- 13 sites in Austria, Spain
- Volunteers
- 28 people
- Sponsor
- MedSIR
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
This phase I/II trial studies the best dose and effect of pimasertib in combination with bintrafusp alfa in treating patients with cancer that has spread to the brain (brain metastases).
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Hormone Receptor Positive Breast Adenocarcinoma
- Trial name
- NCT04789668
- Testing
- Bintrafusp Alfa, Pimasertib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
This pilot trial studies the side effects of giving pembrolizumab together with stereotactic radiosurgery to treat patients with melanoma or non-small cell lung cancer that has spread to the brain.
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Mucosal Melanoma, Ocular Melanoma
- Trial name
- NCT02858869
- Testing
- Pembrolizumab, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Emory University
Brain Metastases, Adult
Prospective Double Arm Randomized Trial: WBRT Alone and WBRT Plus Silibinin
The occurrence of brain metastases (BMs) is increasing given the availability of a more accurate radiological imaging such as MRI for detecting also small brain lesions and the most effective systemic therapy able to control…
- Trial name
- NCT05793489
- Testing
- Silibinin
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- Istituto Clinico Humanitas
Brain Metastases, Glioma of Brain
Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases
Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) is a potentially powerful diagnostic tool for the management of brain cancer and other conditions in which the blood-brain barrier is compromised.
- Conditions
- Brain Metastases, Glioma of Brain, Brain Tumor, Metastatic Melanoma
- Trial name
- NCT03698162
- Testing
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Bevacizumab Injection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Southern California
Glioblastoma, Brain Metastases
Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis
This is two parallel studies to examine pharmacokinetic (PK), pharmacodynamic (PD), and pharmacogenetic (PG) endpoints following short-interval therapy (10-14) daily doses without dose reduction and interruption) with the ALK…
- Trial name
- NCT02605746
- Testing
- ceritinib 750mg
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Metastases to Brain
Comparative Evaluation of Two Different Radiosurgery
Randomized double arm phase III study to evaluate feasibility and safety of Gamma Knife radiosurgery and Linac Based (Edge) radiosurgery in brain metastatic patients
- Trial name
- NCT02355613
- Testing
- Radiosurgery with Gamma Knife Perfexion, Linac-based Radiosurgery with EDGE
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Istituto Clinico Humanitas
Brain Metastases, Adult, Brain Tumor - Metastatic
Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
The goal of this study is to evaluate the feasibility and effectiveness of same-day radiation planning and treatment. The study will shorten the time interval between radiation planning (radiation mapping) and radiation…
- Conditions
- Brain Metastases, Adult, Brain Tumor - Metastatic, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Extra-cranial Solid Tumors
- Trial name
- NCT07132190
- Testing
- Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ayal A. Aizer, MD
Brain Metastases, Lung Cancer
Brigatinib Before Brain Irradiation Trial (B3i Trial)
This is a single arm phase II study of brigatinib alone for patients with brain metastases from anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC), who have either not been treated previously with a…
- Trial name
- NCT04634110
- Testing
- Brigatinib
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- University of Colorado, Denver
Non-small Cell Lung Cancer, Histiocytic Neoplasm
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer…
- Conditions
- Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
- Trial name
- NCT05786924
- Testing
- S241656, FOLFOX6/FOLFOX7, FOLFIRI
- Where
- 49 sites in United States, Australia and 8 more
- Volunteers
- 554 people
- Sponsor
- Institut de Recherches Internationales Servier
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.